Raymond James Starts BridgeBio Oncology Therapeutics, In (BBOT) at Outperform

Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Outperform rating and a price target of $24.00.

The analyst comments "We are initiating coverage of BridgeBio Oncology (BBOT) with an Outperform rating and a price target price of $24. Our rating is based on four points: 1) We see the preliminary activity and safety profile of BBO-8520, a KRAS G12C selective inhibitor, observed in a Phase 1 NSCLC trial as promising. BBO-8520 is poised to become a new contender in the 1L NSCLC setting with pembrolizumab combination data as well. 2) The company’s pan-KRAS inhibitor, BBO-11818, has a broad and potent inhibitory activity while avoiding NRAS/HRAS inhibition with early signals of dose response. 3) We view the RAS:PI3Kα breaker, BBO-10203, as a unique angle to break into metastatic breast cancer that can potentially evolve into a differentiated drug class pending initial Phase 1 combination results in 2H 2026. 4) The company is well capitalized to get through proof of concept updates for all assets. Our confidence is tempered by crowding in the KRAS inhibitor field."

For an analyst ratings summary and ratings history on BridgeBio Oncology Therapeutics, In click here. For more ratings news on BridgeBio Oncology Therapeutics, In click here.

Shares of BridgeBio Oncology Therapeutics, In closed at $13.30 yesterday.

You May Also Be Interested In

• Bumble Inc. (BMBL) PT Lowered to $3.20 at Citi
• Redwood AI acquires Quantum.IQ in an all-share deal
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c